Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
about
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesPharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsSystematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonInitial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes.A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Linagliptin: from bench to bedside.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes.
P2860
Q24568148-079C58CB-4629-4884-8D8B-F8143DE82469Q26749524-7F14B6CD-0F72-482A-9687-F9D14E018FEEQ26772081-586714E8-5A1B-4732-8BA9-3BA445B69A3EQ28071764-A201BDB2-FE64-4F0B-A35C-CA9986C46282Q28546797-6BCD3991-A469-494B-B6C2-8FC96150D28DQ30240823-06EDBB80-D12F-47EA-A214-78F30D3CF620Q33785197-1DF45117-9682-4AB4-BED7-C8DB52FFA139Q34804865-D3FBAEED-65D1-4093-AA23-FDD7D4FF0368Q34824247-9A3C2DD7-BD71-475F-BF2A-D9461828065EQ36730226-A020420B-30BF-4BA7-AEBC-FC8F9037E1DCQ38062881-1A85356D-0E18-49CE-9853-C6283A33A999Q38078436-38FD0E9F-BC09-49C2-9683-13906BA8BEC2Q38082848-9F0B2824-DABB-48EE-BEB0-3016858EC46CQ38211881-3F1B5D02-599F-429B-BE38-25FEEB522063Q38213703-0C40E69B-D7A4-4E26-B933-F93BEAD76DFBQ38258278-D62AC575-53FC-47A0-A50B-6773898B02E0Q38618835-62650489-64D3-478A-B632-E7F0BAC3E4AFQ38795046-5465CFF8-DE4C-4C2D-95FC-96BBFC955855Q40487459-DEE25B84-BF5A-4D7D-9A5E-3D42CFE8BFFFQ40803621-9379A979-839F-4CF4-BD36-A5A1108A8255Q42633492-B7E39203-2A92-4D2C-A4FC-FDCD0391AA50Q55176938-69BB9D00-2D1A-40F0-8405-5309E8804859
P2860
Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@en
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@nl
type
label
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@en
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@nl
prefLabel
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@en
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1476
Efficacy and safety of linagli ...... ind, placebo-controlled trial.
@en
P2093
Elizabeth Rafeiro
Hans-Juergen Woerle
Robert Toorawa
Sonja Weber-Born
Stuart A Ross
Thomas Meinicke
P304
P356
10.1185/03007995.2012.714360
P407
P577
2012-08-13T00:00:00Z